<DOC>
	<DOC>NCT02715466</DOC>
	<brief_summary>This prospective, double-blind randomized controlled trial evaluates the differences in terms of efficacy and safety of gelatin based resuscitation as compared to crystalloid based resuscitation in two parallel groups of patients with severe sepsis / septic shock.</brief_summary>
	<brief_title>Gelatin in ICU and Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Hypovolemia</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Male or female patients ≥ 18 and ≤ 85 years of age Women of child bearing potential must test negative on standard pregnancy test (urine or serum) Patients with body weight ≥ 55 kg and ≤ 140 kg and body mass index (BMI) ≥ 18 kg/m2 and ≤ 35 kg/m2 Patients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after diagnosis Patients already treated with antibiotic therapy (prior to randomization) Patient who are fluid responsive. Fluid responsiveness is defined as increase of at least 10% in mean arterial pressure (MAP) after PLR (Passive Leg Raising) Signed informed consent by patient, legal representative or authorized person or deferred consent Administration of artificial colloids within the 24 hours prior to randomization Death expected within the next 48 hours (moribund patients as defined by ASA ≥ class V) Patients whose medical condition does preclude the PLR (Passive Leg Raising) manoeuvre Patients for whom the need of pressure infusions are expected Requirement for renal support (either continuous or discontinuous techniques, including intermittent haemodialysis, haemofiltration and haemodiafiltration) Patients receiving heparin / anticoagulation therapy Acutely burned patients Contraindications according to summary of product characteristics of investigational test and reference product Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>